Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Standard BioTools Inc
LAB
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.6433
0.0143
2.27%
Dern. MÀJ: Oct 19, 4:19 PM
$0.6280
-0.001
-0.16%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Standard BioTools Financials
Standard BioTools (LAB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Standard BioTools Q2 EPS $(0.07) Misses $(0.03) Estimate, Sales $20.104M Miss $20.805M Estimate
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is a 22.22 percent increase over losses of $(0.09) per share
Benzinga Newsdesk
PRO
Standard BioTools Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $81.504M Est
Standard BioTools (NASDAQ:LAB) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $81.504 million estimate.
Benzinga Newsdesk
PRO
Standard BioTools Q1 EPS $(0.04) Beats $(0.06) Estimate, Sales $21.146M Beat $17.914M Estimate
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.06) per share from
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
Standard BioTools Q4 Earnings Report: What Investors Need to Know
Benzinga Insights
PRO
Standard BioTools Sees FY2026 Sales $80.000M-$85.000M vs $79.727M Est
Benzinga Newsdesk
